Until recently, cancer registries have only collected cancer clinical stage at diagnosis, before any therapy, and pathological stage after surgical resection, provided no treatment has been given before the surgery, but they have not collected stage data after neoadjuvant therapy (NAT). Because NAT is increasingly being used to treat a variety of tumors, it has become important to make the distinction between both the clinical and the pathological assessment without NAT and the assessment after NAT to avoid any misunderstanding of the significance of the clinical and pathological findings. It also is important that cancer registries collect data after NAT to assess response and effectiveness of this treatment approach on a population basis. The prefix y is used to denote stage after NAT. Currently, cancer registries of the American College of Surgeons' Commission on Cancer only partially collect y stage data, and data on the clinical response to NAT (yc or posttherapy clinical information) are not collected or recorded in a standardized fashion. In addition to NAT, nonoperative management after radiation and chemotherapy is being used with increasing frequency in rectal cancer and may be expanded to other treatment sites. Using examples from breast, rectal, and esophageal cancers, the pathological and imaging changes seen after NAT are reviewed to demonstrate appropriate staging.

中文翻译：

---

实体瘤新辅助治疗后当前和未来的癌症分期

直到最近，癌症登记处只收集诊断时、任何治疗前和手术切除后病理分期的癌症临床分期，前提是手术前没有给予治疗，但他们没有收集新辅助治疗（NAT）后的分期数据。由于 NAT 越来越多地用于治疗各种肿瘤，因此区分无 NAT 的临床和病理评估与 NAT 后的评估变得很重要，以避免对临床和病理结果的重要性产生任何误解。癌症登记处收集 NAT 后的数据以评估这种治疗方法在人群基础上的反应和有效性也很重要。前缀 y 用于表示 NAT 之后的阶段。目前，美国外科医师学会癌症委员会的癌症登记处仅部分收集 y 阶段数据，并且未以标准化方式收集或记录对 NAT 的临床反应数据（yc 或治疗后临床信息）。除了 NAT 之外，放疗和化疗后的非手术治疗在直肠癌中的使用频率越来越高，并且可能会扩展到其他治疗部位。使用乳腺癌、直肠癌和食道癌的例子，回顾 NAT 后看到的病理和影像学变化，以证明适当的分期。放疗和化疗后的非手术治疗在直肠癌中的使用频率越来越高，并可能扩展到其他治疗部位。使用乳腺癌、直肠癌和食道癌的例子，回顾 NAT 后看到的病理和影像学变化，以证明适当的分期。放疗和化疗后的非手术治疗在直肠癌中的使用频率越来越高，并可能扩展到其他治疗部位。使用乳腺癌、直肠癌和食道癌的例子，回顾 NAT 后看到的病理和影像学变化，以证明适当的分期。